Sionna Therapeutics, a clinical-stage biopharmaceutical company focused on cystic fibrosis (CF), announced participation in two investor conferences in November 2026. Management will engage in fireside chats at Guggenheim's Healthcare Innovation Conference on November 9 and Stifel’s Healthcare Conference on November 10. These events provide updates on Sionna’s efforts to develop novel medicines targeting the CFTR protein to improve CF treatment. Live webcasts and replays will be available on Sionna’s investor website, offering investors insight into the company’s progress and future plans.
Sionna Therapeutics' upcoming participation in November 2026 investor conferences is noted alongside Pluang's Health-sector market data. For readers following Health-sector stocks, here is Pluang's market snapshot as of Nov 02, 2026 19:21 WIB: out of 150 priced US Health-sector stocks, 82 rose and 47 fell today. Notable movers include IDXX (IDEXX Laboratories, Inc.) at USD 585.99 with a 1-day change of +6.31% and a typical hold time on Pluang of 47 days, FLNA (Cassava Sciences Inc) at USD 0.66 with +6.11%, and DNA (Ginkgo Bioworks Holdings Inc) at USD 11.79 with +4.99%.
The global bio-based construction polymer market, valued at $18.2 billion in 2025, is projected to grow to $35 billion by 2033 at an 8.3% CAGR. Growth is fueled by rising demand for sustainable building materials that reduce greenhouse gas emissions ...
Annual Over-the-Air (OTA) software updates for software-defined vehicles (SDVs) are projected to reach over 2 billion globally by 2035, up from 546 million in 2025, driven by rising SDV sales and advanced vehicle software platforms. Level 3 and above...
Fram Wind Solutions AS, a joint venture partly owned by BW Offshore, secured a NOK 1.94 billion grant from Enova to develop a floating offshore wind project featuring two 18.5 MW turbines, the largest globally, with a combined capacity of 37 MW. The ...
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
